Business Card for Catherine Elflein:


Director of Treasury and Risk Management
Summit, NJ area
Email Avail: 3 Day Free Trial


86 Morris Ave
Summit, NJ 07901

Tel: (908) 673-9000

Last updated on 2017-10-21


About Catherine Elflein:

Catherine Elflein works as an Director of Treasury and Risk Management for Celgene at Summit, NJ. The company's webpage is http://www.celgene.com. For email, phone number and executive profiles for Director of Treasury and Risk Management and other executives of Celgene at Summit, NJ, check Celgene at Joesdata.com. Not the Catherine Elflein you are looking for? Do a quick search in our website and find other people named Catherine Elflein.
Catherine Elflein's Work History:
No information available..

Catherine Elflein's Education:
No information available..

Catherine Elflein's Co-workers:
As of September 30, 2020, Catherine Elflein has 953 co-workers under the company name Celgene at Joesdata.com.

About Celgene:

Celgene Corporation is a global biopharmaceutical company engaged in the discovery, development and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases. It is engaged in the research and development, which is designed to bring new therapies to market, and is engaged in research in several scientific areas that may deliver therapies, focusing areas, such as intracellular signaling pathways in cancer and immune cells, immunomodulation in cancer and autoimmune diseases, and therapeutic application of cell therapies. Its primary commercial stage products include REVLIMID, VIDAZA, THALOMID, ABRAXANE and ISTODAX. Additional sources of revenue include a licensing agreement with Novartis, which entitles it to royalties on FOCALIN XR and the entire RITAL...... (Source: SEC reports)

Company News:
2018-09-12 17:30:52
OTEZLA (Apremilast) Showed Meaningful Improvements in Clinical and Quality-of-Life Measures of Psoriasis Beyond Those Captured by Assessing Skin Alone
2018-07-10 19:24:21
Anti-PD-L1 Immunotherapy Plus ABRAXANE Significantly Reduced the Risk of Disease Worsening or Death in Patients with Metastatic or Locally Advanced Triple Negative Breast Cancer in Phase III IMpassion130 Study
2018-07-10 17:30:42
Anti-PD-L1 Immunotherapy Plus ABRAXANE Significantly Reduced the Risk of Disease Worsening or Death in Patients with Metastatic or Locally Advanced Triple Negative Breast Cancer in Phase III IMpassion130 Study
2018-06-03 18:54:37
Results of Phase III RELEVANCE Study Comparing REVLIMID plus Rituximab (R2) Versus Rituximab Plus Chemotherapy in Patients with Previously Untreated Follicular Lymphoma to be Presented at ASCO 2018
2018-06-03 17:31:02
Results of Phase III RELEVANCE Study Comparing REVLIMID plus Rituximab (R2) Versus Rituximab Plus Chemotherapy in Patients with Previously Untreated Follicular Lymphoma to be Presented at ASCO 2018
2018-06-01 18:54:20
Results of Phase III OPTIMISMM Study Presented at ASCO 2018 Showed the PVd Triplet Improved PFS in Early Lines of Relapsed or Refractory Multiple Myeloma
2018-06-01 17:30:39
Results of Phase III OPTIMISMM Study Presented at ASCO 2018 Showed the PVd Triplet Improved PFS in Early Lines of Relapsed or Refractory Multiple Myeloma
2018-05-22 18:54:17
Celgene to Present New and Updated Data across a Range of Blood Diseases at EHA 2018
2018-05-22 17:30:52
Celgene to Present New and Updated Data across a Range of Blood Diseases at EHA 2018
2018-05-16 18:54:19
Celgene to Present New Clinical Data in Blood Cancer and Solid Tumor Therapies at Upcoming American Society of Clinical Oncology (ASCO) Scientific Sessions

People in the same industry: